Cancer - The mitochondrial connection

Biologia

Volumn 62, Issue 4, 2007, Pages 371-380

  Paul, Manash K ^a   Mukhopadhyay, Anup K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Apoptosis; Cancer; Chemotherapy; Drug targeting; Mitochondria; Mitochondrial DNA mutations

Indexed keywords

EID: 49949109126     PISSN: 00063088     EISSN: 13369563     Source Type: Journal    
DOI: 10.2478/s11756-007-0094-4     Document Type: Article

References (81)

1. Adams J.M. & Cory S. 2002. Apoptosomes: engines for caspase activation. Curr. Opin. Cell Biol. 14: 715-720.
2. Adrain C. & Martin S.J. 2001. The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem. Sci. 26: 390-397.
3. Alanso A., Martin P., Albarran C., Aquilera B., Garcia O., Guzman A., Oliva H. & Sancho M. 1997. Detections of somatic mutations in the mitochondrial DNA control regions of colorectal and gastric tumors by heteroduplex and single strand conformation analysis. Electrophoresis 18: 682-685.
4. Ashkenazi A. & Dixit V.M. 1998. Death receptors: signaling and modulation. Science 281: 1305-1308.
5. Bernal S.D., Lampidis T.J., McIsaac R.M. & Chen L.B. 1983. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science 222: 169-172.
6. Bossy-Wetzel E. & Green D.R. 1999. Apoptosis: checkpoint at the mitochondrial frontier. Mutat. Res. 434: 243-251.
7. Brandon M., Baldi P. & Wallace D.C. 2006. Mitochondrial mutations in cancer. Oncogene 25: 4647-4642.
8. Bratton S.B. & Cohen G.M. 2001. Apoptotic death sensor: an organelle's alter ego. Trends Pharmacol. Sci. 22: 306-315.
9. Burgart L.J., Zheng J., Shu Q., Strickler J.G. & Shibata D. 1995. Somatic mitochondrial mutation in gastric cancer. Am. J. Pathol. 147: 1105-1111.
10. Carew J.S. & Huang P. 2002. Mitochondrial defects in cancer. Mol. Cancer 1: 9-32.
11. Cerutti P.A. 1985. Prooxidant states and tumor promotion. Science 227: 375-381.
12. Chang H. 2000. Proteases for cell suicide: functions and regulation of caspases. Microbiol. Mol. Biol. Rev. 64: 821-846.
13. Clayton D.A. & Vinograd J. 1967. Circular dimers and catenate forms of mitochondrial DNA in human leukaemic leucocytes. Nature 216: 652-657.
14. Corral M., Paris B., Baffet G., Tichonicky L., Guguen-Guillouzo C., Kruh J. & Defer N. 1989. Increased level of the mitochondrial ND5 transcript in chemically induced rat hepatomas. Exp. Cell Res. 184: 158-166.
15. Cross R. 1994. Our primary source of ATP. Nature 370: 594-596.
16. Curtin J.F., Donovan M. & Cotter T.G. 2002. Regulation and measurement of oxidative stress in apoptosis. J. Immunol. Methods 265: 49-72.
17. Czernin J. & Phelps M.E. 2002. Positron emission tomography scanning: current and future applications. Annu. Rev. Med. 53: 89-112.
18. Degterev A., Boyce M. & Yuan J. 2001. The channel of death. J. Cell Biol. 155: 695-698.
19. Desagher S. & Martinou J.C. 2000. Mitochondria as the central control point of apoptosis. Trends Cell. Biol. 10: 369-377.
20. Duchen M.R. 2004. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol. Aspects Med. 25: 365-451.
21. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., Bredesen D.E. & Pasqualini R. 1999. Anticancer activity of targeted proapoptotic. Nat. Med. 5: 1032-1038.
22. Fantin V.R., Berardi M.J., Scorrano L., Korsmeyer S.J. & Leder P. 2002. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2: 29-42.
23. Fliss M.S., Usadel H., Caballero O.L., Wu L., Buta M.R., Eleff S.M., Jen J. & Sidransky D. 2000. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287: 2017-2019.
24. Gatenby R.A. & Gillies R.J. 2004. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer 4: 891-899.
25. Grad J.M., Cepero E. & Boise L.H. 2001. Mitochondria as targets for established and novel anticancer agents. Drug Resist. Updates 4: 85-91.
26. Green D.R. & Evan G.I. 2002. A matter of life and death. Cancer Cell 1: 19-30.
27. Gross A., McDonnell J.M. & Korsmeyer S.J. 1999. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 13: 1899-1911.
28. Hail Jr N. 2005. Mitochondria: a novel target for the chemoprevention of cancer. Apoptosis 10: 687-705.
29. Hengartner M.O. 2000. The biochemistry of apoptosis. Nature 407: 770-776.
30. Hibi K., Nakayama H., Yamazaki T., Takase T., Taguchi M., Kasai Y., Ito K., Akiyama S. & Nakao A. 2001. Mitochondrial DNA alteration in esophageal cancer. Int. J. Cancer 92: 319-321.
31. Holt I.J., Harding A.E. & Morgan-Hughes J.A. 1988. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 331: 717-719.
32. Horton T.M., Petros J.A., Heddi A., Shoffner J., Kaufman A.E., Graham Jr S.D., Gramlich T. & Wallace D.C. 1996. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer 15: 95-101.
33. Jeronimo C., Nomoto S., Caballero O.L., Usadel H., Henrique R., Varzim G., Oliveira J., Lopes C., Fliss M.S. & Sidransky D. 2001. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 20: 5195-5198.
34. Jones J.B., Song J.J., Hempen P.M., Parmigiani G., Hruban R.H. & Kern S.E. 2001 Detection of mitochondrial DNA mutations in pancreatic cancer offers a "massive" advantage over detection of nuclear DNA mutations. Cancer Res. 61: 1299-1304.
35. Koya K., Li Y., Wang H., Ukai T., Tatsuta N., Kawakami M., Shishido T. & Chen L.B. 1996. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res. 56: 538-543.
36. Kim J. & Dang C.V. 2006. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66: 8927-8929.
37. Kuin A., Alders M., Van der Valk M.A., Frey A., Schmidt H.H. & Smets L.A. 1998. Renal toxicity of the neuron-blocking and mitochondriotropic agent m-iodobenzylguanidine. Cancer Chemother. Pharmacol. 42: 37-45.
38. Lampidis T.J., Bernal S.D., Summerhayes I.C. & Chen L.B. 1983. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res. 43: 716-720.
39. Lewis L.M. & Indig G.L. 2002. Effect of dye aggregation on triarylmethane-mediated photoinduced damage of hexokinase and DNA. J. Photochem. Photobiol. 67: 139-148.
40. Liang B.C. & Hays L. 1996. Mitochondrial DNA copy number changes in human gliomas. Cancer Lett. 105: 167-173.
41. Liberman A., Topaly V.P., Tsofina L.M., Jasaitis A.A. & Skulachev V.P. 1969. Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature 222: 1076-1078.
42. Liu V.W., Shi H.H., Cheung A.N., Chiu P.M., Leung T.W., Nagley P., Wong L.C. & Ngan H.Y. 2001. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res. 61: 5998-6001.
43. Luciakova K. & Kuzela S. 1992. Increased steady state levels of several mitochondrial and nuclear gene transcripts in rat hepatoma with a low content of mitochondria. Eur. J. Biochem. 205: 1187-1193.
44. Luft R., Ikkos D., Palmieri G., Ernster L. & Afzelius B. 1962. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J. Clin. Invest. 41: 1776-1804.
45. Marcucci G., Byrd J.C., Dai G., Klisovic M.I., Kourlas P.J., Young D.C., Cataland S.R., Fisher, D.B. Lucas D., Chan K.K., Porcu P., Lin Z.P., Farag S.F., Frankel S.R., Zwiebel J.A., Kraut E.H., Balcerzek S.P., Bloomfield C.D., Grever M.R. & Caliguiri M.A. 2003. Phase I and pharmacodynamic studies of G3139, a Bcl-2 antisense poligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101: 425-432.
46. Maximo V., Soares P., Seruca R., Rocha A.S., Castro P. & Sobrinho-Simoes M. 2001. Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. Genes Chromosomes Cancer 32: 136-143.
47. Maximo V., Soares P., Seruca R. & Sobrinho-Simoes M. 1999. Comments on: mutations in mitochondrial control region DNA in gastric tumors of Japanese patients. Eur. J. Cancer. 35: 1407-1408.
48. Modica-Napolitano J.S., Koya K., Weisberg E., Brunelli B.T., Li Y. & Chen L.B. 1996. Selective damage to carcinoma mitochondria by the rhodocyanine MKT-077. Cancer Res. 56: 544-550.
49. Modica-Napolitano J.S. & Singh K.K. 2002. Mitochondria as targets for detection and treatment of cancer. Expert Rev. Mol. Med. 11: 1-19.
50. Morgan J., Whitaker J.E. & Oseroff A.R. 1998. GRP78 induction by calcium ionophore potentiates photodynamic therapy using the mitochondrial targeting dye victoria blue. Photochem. Photobiol. 67: 155-164.
51. Muindi J.R., Sinha B.K., Gianni L. & Myers C.E. 1984. Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Lett. 172: 226-230.
52. Nass M.M. & Nass S. 1963. Intramitochondrial fibers with DNA characteristics. I. Fixation and electron staining reactions. J. Cell Biol. 19: 593-611.
53. Nijhawan P.L., Budihardjo D., Srinivasula I., Ahmad S.M., Alnemri E.S. & Wang X. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489.
54. Oseroff A.R., Ohuoha D., Ara G., McAuliffe D., Foley J. & Cincotta L. 1986. Intramitochondrial dyes allow selective in vitro photolysis of carcinoma cells. Proc. Natl. Acad. Sci. USA 83: 9729-9733.
55. Parrella P., Xiao Y., Fliss M., Sanchez-Cespedes M., Mazzarelli P., Rinaldi M., Nicol T., Gabrielson E., Cuomo C., Cohen D., Pandit S., Spencer M., Rabitti C., Fazio V.M. & Sidransky D. 2001. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res. 61: 7623-7626.
56. Penta J.S., Johnson F.M., Wachsman J.T. & Copeland W.C. 2001. Mitochondrial DNA in human malignancy. Mut. Res. 488: 119-133.
57. Pettepher C.C., LeDoux S.P., Bohr V.A. & Wilson G.L. 1991. Repair of alkali-labile sites within the mitochondrial DNA of RINr 38 cells after exposure to the nitrosourea streptozotocin. J. Biol. Chem. 266: 3113-3117.
58. Polyak K., Li Y., Zhu H., Lengauer C., Willson J.K., Markowitz S.D., Trush M.A., Kinzler K.W. & Vogelstein B. 1998. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat. Genet. 20: 291-293.
59. Qin H., Srinivasula S.M., Wu G., Fernandes-Alnemri T., Alnemri E.S. & Shi H. 1999. Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1. Nature 399: 549-557.
60. Ravagnan L., Marzo I., Constantini P., Susin S.A., Zamzami N., Petit P.X., Hirsch F., Goulbern M., Poupon M., Miccoli L., Xie Z., Reed J.C. & Kroemer G. 1999. Lonidamine triggers apoptosis via direct Bcl-2 inhibited effect on the mitochondrial permeability transition pore. Oncogene 18: 2537-2546.
61. Regula K.M., Ens K. & Kirshenbaum L.A. 2003. Mitochondria-assisted cell suicide: a license to kill. J. Mol. Cell Cardiol. 35: 559-567.
62. Rideout D., Bustamante A. & J. Patel. 1994. Mechanism of inhibition of FaDu hypopharyngeal carcinoma cell growth by tetraphenylphosphonium chloride. Int. J. Cancer 57: 247-253.
63. Robertson J.D., Gogvadez V., Zhivotovsky B. & Orrenius S. 2000. Distinct pathways for stimulation of cytochrome c release by etoposide. J. Biol. Chem. 276: 32438-32443.
64. Singh K.K, Russell J., Sigala B., Zhang Y., Williams J. & Keshav K.F. 1999. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 18: 6641-6646.
65. Sun X., Wong J.R., Song K., Hu J., Garlid K.D. & Chen L.B. 1994. AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity. Cancer Res. 54: 1465-1471.
66. Szewczyk A. & Wojtczak L. 2002. Mitochondria as a pharmacological target. Pharmacol. Rev. 54: 101-128.
67. Tamura G., Nishizuka S., Maesawa C., Suzuki Y., Iwaya T., Sakata K., Endoh Y. & Motayama T. 1999. Mutations in mitochondrial control region DNA in gastric tumours of Japanese patients. Eur. J. Cancer 35: 316-319.
68. Tan D., Bai R., & Wong L.C. 2002. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res. 62: 972-976.
69. Tsang W.Y. & Lemire B.D. 2003. The role of mitochondria in the life of the nematode, Caenorhabditis elegass. Biochim. Biophys. Acta. 1638: 91-105.
70. Tsujimoto Y. & Shimizu S. 2000. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ. 7: 1174-1181.
71. Verma M., Kagan J., Sidransky D. & Srivastava S. 2003. Proteomic analysis of cancer-cell mitochondria. Nature Rev. Cancer 3: 789-795.
72. Wallace D.C., Singh G., Lott M.T., Hodge J.A., Schurr T.G., Lezza A.M., Elsas L.J. & Nikoskelainen E.K. 1988. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242: 1427-1430.
73. Wallace D.C. 1997. Mitochondrial DNA in aging and disease. Sci. Am. 277: 40-47.
74. Wang X. 2001. The expanding role of mitochondria in apoptosis. Genes Dev. 15: 2922-2933.
75. Weiss M.J., Wong J.R., Ha C.S., Bleday R., Salem R.R., Steele G.D. & Chen L.B. 1987. Dequalinium, a tropical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc. Natl. Acad. Sci. USA 84: 5444-5448.
76. Weissig V., Boddapati S.V., Cheng S., D'souza G.G.M. 2006. Liposome and liposome-like vesicles for drug and DNA delivery in mitochondria. J. Liposome Res. 16: 249-264.
77. Weissig V., Cheng S.M. & D'souza G.G. 2004. Mitochndrial pharmaceutics. Mitochondrion 3: 229-244.
78. Weissig V. & Torchilin V.P. 2001. Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems. Adv. Drug Deliv. Rev. 49: 127-149.
79. Yakes F.M. & Houten B.V. 1997. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl. Acad. Sci. USA 94: 514-519.
80. Yeh J.J., Lunetta K.L., van Orsouw N.J., Moore Jr F.D., Mutter G.L., Vijg J., Dahia P.L. & Eng C. 2000. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 19: 2060-2066.
81. Zimmermann K.C., Bonzon C. & Green D.R. 2001. the machinery of programmed cell death. Pharmacol. Ther. 92: 57-70.